These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 9531118)

  • 1. Fecal occult blood testing: clinical value and limitations.
    Simon JB
    Gastroenterologist; 1998 Mar; 6(1):66-78. PubMed ID: 9531118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Screening for colorectal tumors using fecal occult blood studies].
    Restellini A; Margalith D; Bauerfeind P; Guyot J; Ollyo JB; Gonvers JJ; Blum AL
    Ther Umsch; 1989 Jun; 46(6):389-97. PubMed ID: 2667190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests.
    Levin B; Hess K; Johnson C
    Arch Intern Med; 1997 May; 157(9):970-6. PubMed ID: 9140267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colon cancer screening strategies.
    Agrawal J; Syngal S
    Curr Opin Gastroenterol; 2005 Jan; 21(1):59-63. PubMed ID: 15687886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
    Smith A; Young GP; Cole SR; Bampton P
    Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Periodic health examination, 1994 update: 2. Screening strategies for colorectal cancer. Canadian Task Force on the Periodic Health Examination.
    Solomon MJ; McLeod RS
    CMAJ; 1994 Jun; 150(12):1961-70. PubMed ID: 7980760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
    Quintero E
    Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population colorectal cancer screening with fecal occult blood test.
    Rennert G; Rennert HS; Miron E; Peterburg Y
    Cancer Epidemiol Biomarkers Prev; 2001 Nov; 10(11):1165-8. PubMed ID: 11700264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of three stool tests for colorectal cancer screening.
    Greenwald B
    Medsurg Nurs; 2005 Oct; 14(5):292-9; quiz 300. PubMed ID: 16318108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colorectal cancer screening through detection of fecal occult blood in a controlled health zone.
    Tárraga P; García-Olmo D; Celada A; García-Molinero Mf; Divison JA; Casado C
    Rev Esp Enferm Dig; 1999 May; 91(5):335-44. PubMed ID: 10362875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.
    Imperiale TF; Ransohoff DF; Itzkowitz SH; Turnbull BA; Ross ME;
    N Engl J Med; 2004 Dec; 351(26):2704-14. PubMed ID: 15616205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
    van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
    Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is it reasonable to use faecal occult blood test for colorectal cancer screening?
    Musil D; Tillich J
    Acta Univ Palacki Olomuc Fac Med; 1999; 142():119-21. PubMed ID: 10743740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas.
    Macrae FA; St John DJ
    Gastroenterology; 1982 May; 82(5 Pt 1):891-8. PubMed ID: 7060910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of fecal occult-blood tests for colorectal-cancer screening.
    Allison JE; Tekawa IS; Ransom LJ; Adrain AL
    N Engl J Med; 1996 Jan; 334(3):155-9. PubMed ID: 8531970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Informative value of Hemoccult test according to the number of positive slides in mass screening of colorectal cancer].
    Tazi MA; Faivre J; Lejeune C; Dassonville F; Benhamiche AM
    Bull Cancer; 1998 Dec; 85(12):1055-9. PubMed ID: 9917557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study.
    Hoepffner N; Shastri YM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein J
    Aliment Pharmacol Ther; 2006 Jan; 23(1):145-54. PubMed ID: 16393292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.